Skip to content

Clinical study of Yigu Decoction regulating intestinal microecology in patients with osteoporotic hip fracture

Clinical study of Yigu Decoction regulating intestinal microecology in patients with osteoporotic hip fracture

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005594
Enrollment
Unknown
Registered
2022-02-03
Start date
2021-12-31
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Treatment:conventional therapy + surgery + Yigu Decoction
control:conventional therapy + surgery

Sponsors

The Third Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 95 Years

Inclusion criteria

Inclusion criteria: (1) In line with the diagnostic criteria and age criteria of this subject: men are over 70 years old and women are generally more than 20 years after menopause; (2) Those who did not take anti osteoporosis drugs within 3 months were included in the criteria; (3) Patients willing to take traditional Chinese medicine decoction; (4) Conform to normal height / body mass index, activity level (physical activity scale, PAS) = 180 points, no bad habits; (5) Sign the clinical study informed consent form.

Exclusion criteria

Exclusion criteria: (1) Non hip trochanteric fracture, such as femoral neck fracture, femoral head fracture, acetabular fracture and other diseases. (2) Patients with high-energy injury and multiple fractures; Postmenopausal women whose menopause time is less than 20 years. (3) It is complicated with serious chronic primary diseases such as cardio cerebrovascular, liver, kidney, respiratory system and hematopoietic system, various digestive system diseases, psychiatric patients, and the following secondary osteoporosis patients: ? endocrine cortisol increase, hyperthyroidism, primary hyperparathyroidism, acromegaly, hypogonadism Diabetes and so on. ? Nutritional protein deficiency, vitamin C deficiency, low calcium diet, alcoholism, etc. ? Hereditary osteogenesis imperfecta chromosome abnormality. ? Liver disease. ? Kidney disease chronic nephritis hemodialysis. ? Drugs: corticosteroids, antiepileptic drugs, antineoplastic drugs (such as methotrexate), heparin, etc. ? Disuse systemic osteoporosis can be seen in long-term bed rest, paraplegia, space flight, etc; Local bone atrophy can be seen after fracture, sudecks bone atrophy, post injury bone atrophy, etc. ? Gastrectomy for gastrointestinal malabsorption. ? Rheumatoid arthritis. ? Tumor, multiple myeloma, metastatic cancer, monocytic leukemia, mast cell disease, etc. ? Other causes include osteopenia, transient or migratory osteoporosis.

Design outcomes

Primary

MeasureTime frame
bone mineral density;vitamin D;Intestinal flora;

Secondary

MeasureTime frame
TCM syndrome score;visual analogue scale;Comprehensive evaluation of quality of life;

Countries

China

Contacts

Public ContactChen Zhineng
czneng@163.com13777381630

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026